Abstract: Provided herein are transition metal complexes that are useful in the acceptorless dehydrogenation of various substrates, including alkanes. Also provided are methods of dehydrogenating substrates to provide unsaturated products such as olefins.

Abstract: Novel compositions of matter based on homopiperazine precursor materials and forming a homopiperazine-based ligand are disclosed, along with suitable techniques and materials for the synthesis and utilization thereof. In particular various synthetic schemes and techniques for applying the disclosed compositions of matter as a decontaminating agent. The decontaminating agents include homopiperazine-based ligand-metal complexes that are particularly effective at neutralizing toxicity of nerve agents, pesticides, and other toxic organophosphorus-based compounds. In preferred approaches, the homopiperazine-based ligand-metal complexes act as catalysts to facilitate substitution of a leaving group of the organophosphorus-based compound with a functional group that does not permit the organophosphorus-based compound to inactivate acetylcholinesterase upon introduction of the organophosphorus-based compound to a living organism such as insects and mammals.

Abstract: An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method.

Abstract: The present invention relates to an improved and industriously advantageous process by means of providing coupling/condensing of wet mass of (1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid-O3,O4)bis(acyloxy-O)borate with (S,S)-2,8-diazabicyclo[4.3.0]nonane to give 1-cyclopropyl-7-[S,S]-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride (Moxifloxacin hydrochloride) of Formula-I with high purity.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.

Abstract: The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: The present invention describes metal salen complexes having dianionic counterions. Such complexes can be readily precipitated and provide an economical method for the purification and isolation of the complexes, and are useful to prepare novel polymer compositions.

Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Abstract: The present invention relates to an organometallic complex, to the preparation of said material, to the use of said material and to a light emitting device which transform electric energy into light. The present invention is further related to provide phosphorescent complexes which contribute to extend the life time in operation of said OLEDs and especially when they are involved in the EL. The objectives of this invention are accomplished by iridium complex comprising 7-membered fused ring ligands which are tris-homoleptic or bis-homoleptic with an ancillary ligand.

Abstract: The present invention relates, inter alia, to metal complexes having improved solubility, to processes for the preparation of the metal complexes, to devices comprising these metal complexes and to the use of the metal complexes. M(L)n(L?)m formula 1 where the compound contains a moiety M(L)n of the formula (2) W is equal to the formula (3).

Abstract: Disclosed herein are phosphorescent materials comprising a complex of a metal atom M selected from Ir, Pt, Rh, Pd, Ru and Os and at least one ligand L, wherein the ligand L is represented by formula (1). Also disclosed are organic electroluminescent devices including such phosphorescent materials.

Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

Abstract: The present invention relates to compounds of the formula (I) and to the use thereof in electronic devices, in particular organic electroluminescent devices. Furthermore, the present invention relates to electronic devices comprising at least one compound according to the invention, preferably as emitter material or as charge-transport material.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: Disclosed herein are vinyl-bromides, vinyl-boronic acids and vinyl-boronic acid derivatives useful as synthetic intermediates for the preparation of therapeutic agents. Also disclosed are methods of synthesis of vinyl-bromides, vinyl-boronic acids and vinyl-boronic acid derivatives.

Abstract: The invention relates to novel compositions of disubstituted bipyridyl osmium complexes useful for the synthesis of labeled proteins, nucleic acids, and for the modification of electrodes.

Abstract: The present invention relates to novel bispidon ligands, a method for the production thereof, and the use thereof as a ligand in metal complexes and the selective separation of metals, metal complexes comprising said ligands, method for the production thereof, and the use of such metal complexes in organic synthesis, in bleaching, and in the radiopharmaceutical field.

Abstract: Disclosed are carbenes of the general formula: and including salts thereof, and metal complexes thereof. The carbenes are useful in any reaction where carbenes and carbene-metal complexes are used. The carbenes disclosed herein are particularly useful in asymmetric catalysis.

Abstract: The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.

Abstract: Imidazo[1,2-f]phenanthridine compounds are provided. The compounds have a twisted aryl moiety further substituted by alkyl having four or more atoms. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

Abstract: One aspect of the present invention relates to “boronium” ions that are stable, hydrophobic, room-temperature ionic liquids. In certain embodiments, ionic liquids of the instant invention are represented by the formula [XnBY4?n]+(n?1)(n?1)Z?1, wherein X refers to a Lewis base, Y refers to a substituent covalently bonded to boron, Z?1 is a charge diffuse anion, and x is 2, 3 or 4. In certain embodiments, the ionic liquids of the instant invention are of the general type [X2BY2]+1Tf2N?1, wherein each X is independently a tertiary amine, a N-alkylimidazole or a pyridine; and each B—X bond is a B—N bond.

Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices employing the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1). Since the organic electroluminescent compounds according to the invention have good luminous efficiency and excellent life property of material, OLED's having very good operation life can be manufactured therefrom.

Abstract: The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.

Abstract: Provided is a method for producing a phenol condensate by oxidative condensation of a phenol compound not having a substituted group on at least one ortho-position, in the presence of a specific complex (II) and oxygen, wherein a condensate coupled at para-position of the phenol can be produced in an excellent yield, L-M (X)n??(II) wherein L represents a ligand having 2 to 4 nitrogen atoms as donor atoms, M represents copper ion, nickel ion, cobalt ion, iron ion, manganese ion, chromium ion or vanadyl ion, X represents a counter ion, n is a number of Xs.

Abstract: This invention provides antioxidant cyclic salen-metal compounds, compositions of such antioxidant cyclic salen-metal compounds having superoxide activity, catalase activity and/or peroxidase activity and methods of using such antioxidant cyclic salen-metal compositions to treat or prevent a disease associated with cell or tissue damage produced by free radicals, such as superoxide.

Abstract: An audio visual display system for use positioned at a site of interment such as a cemetery or grave site to provide information to users specifically pertinent to the aspect of memorialization of the site of interment and, in particular, of the individual or individuals buried at this location. The design includes an audio visual displaying device for displaying visual information and playing audio information commemorating the interment site or otherwise pertinent thereto. An input selection means such as a keyboard or touchpad is included for selecting among more than one possible audio and/or visual display modes. A self-contained power supply system is included with an optional solar cell recharging system. The system is completely self-contained and is self-sustained at the site with its own power supply and security system allowing both maintenance and secure access thereto by users.

Abstract: New ruthenium dimeric complexes with high antimetastatic and antitumour activity and remarkable chemical stability are described.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds arc useful, inter alia, for determining the binding and/or receptor sites of the molecules.

Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3-12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds.

Abstract: The present invention relates to compounds of Formula (I): wherein A1 is methylene, ethylene or propylene group and A2 is N or CR5, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Abstract: Complexes of the formula I 1

Abstract: The invention relates to chiral ionic liquids of the general formula

Abstract: This invention provides antioxidant cyclic salen-metal compounds, compositions of such antioxidant cyclic salen-metal compounds having superoxide activity, catalase activity and/or peroxidase activity and methods of using such antioxidant cyclic salen-metal compositions to treat or prevent a disease associated with cell or tissue damage produced by free radicals, such as superoxide.

Abstract: A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C1 to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3 or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3; R5 and R6

Abstract: Bicyclic amino alcohols, whose amino group and hydroxy group are bonded in positions 1,3 adjacent to the bridge, for example 1

Abstract: Fluoroaluminate compounds of formula M+n(AlF4)n− wherein n is 1 to 3 and M+n is N(R2)4, P(R2)4, As(R2)4, HN(R2)3, H2N(R2)2, H3N(R2), (R2)3P═N═P(R2)3, S[N(R2)2]3, (R2)NCN(R)2, (R)2N—(C(R)2)k—N(R)3, and ZHm+m wherein Z is a base capable of accepting m protons, and various cyclic and aryl groups are disclosed as well as processes for their preparation.

Abstract: Disclosed herein is a process for the polymerization of ethylene, norbornenes and styrenes, by contacting in solution a selected nickel compound and a selected compound which is or can coordinated to the nickel with the olefin(s). The polymers produced are useful for films and molding resins.

Abstract: The invention relates to new 1,4,7,10-tetraazacyclododecane derivatives of formula I ##STR1## in which R.sup.1, R.sup.2, X and V have various meanings, their metal complexes, pharmaceutical agents containing these compounds, their use in diagnosis and treatment as well as process for the production of these compounds and agents.

Abstract: An organolithium compound according to the present invention containing a cyclic amino group, has the general formula: ##STR1## wherein R.sub.1 is a divalent alkylene, an oxy- or amino-alkylene, or substituted alkylene having from 6 to about 20 carbon atoms; R.sub.2 is a linear-, branched-, or cyclo-alkylene having from about 2 to about 20 carbon atoms; and the lithium, Li, is bonded directly to a carbon atom of R.sub.2. A method of preparing an organolithium compound containing a cyclic amino group, comprising reacting a cyclic amino organo halide having the general formula ##STR2## where R.sub.1 and R.sub.2 are as above, and X is bromine or chlorine bonded directly to a carbon atom of R.sub.2, with a lithium reactant selected from lithium metal or an organolithium compound.

Abstract: Fluoroaluminate compounds of formula M.sup.+n (AlF.sub.4).sub.n.sup.- wherein n is 1 to 3 and M.sup.+n is N(R.sub.2).sub.4, P(R.sub.2).sub.4, As(R.sub.2).sub.4, HN(R.sub.2).sub.3, H.sub.2 N(R.sub.2).sub.2, H.sub.3 N(R.sub.2), (R.sub.2).sub.3 P.dbd.N.dbd.P(R.sub.2).sub.3, S?N(R.sub.2).sub.2 !.sub.3, ##STR1## (R).sub.2 N--(C(R).sub.2).sub.k --N(R).sub.3, and ZH.sub.m.sup.+m wherein Z is a base capable of accepting m protons, and various cyclic and aryl groups are disclosed as well as processes for their preparation.

Abstract: A compound of formula (I): ##STR1## n which M is a transition metal ion; A is a counter-ion if required;r, s and t are independently 0 to 3 such that r+s+t is in the range of 1 to 3;R.sup.a, R.sup.b, R.sup.c are each independently hydrogen or CH.sub.2 OR' where R' is hydrogen or an organic group;B and E are independently oxygen, CH.sub.2, NR.sup.d in which R.sup.d is alkyl, hydrogen, alkylcarbonyl, or arylcarbonyl or SO.sub.n where n is 0 or an integer 1 or 2, with the proviso that B and E are not simultaneously CH.sub.2 and that when B is oxygen, NR.sup.d or SO.sub.n, then r cannot be 0, and when E is oxygen, NR.sup.d or SO.sub.n, then t cannot be 0;R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are independently hydrogen, alkyl or alkoxy.

Abstract: Compounds of the general formula: ##STR1## wherein m, X, Y, A, R.sub.2 and R.sub.3 are defined in the description, and medicaments containing the same.

Abstract: An anionic initiator system formed by the reaction product of: (1) an organolithium compound with (2) the reaction product of (a) a secondary amine and (b) diisopropenyl benzene, initiates polymerization to produce a polymer containing tertiary amine functional sites incorporated at the head of the polymer chain. A subclass of these polymers can be compounded to exhibit reduced hysteresis over conventionally prepared polymers.

Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 and A are defined within.

Abstract: In enhanced chemiluminescent (ECL) reactions of a fused aromatic diacyl cyclic hydrazide such as luminol, a peroxidase enzyme catalyst, an oxidant such as hydrogen peroxide and an enhancer, it has been found advantageous to use a combination of an organoboron enhancer such as 4-biphenylboronic acid with a non boron-containing enhancer, especially a phenolic or aromatic amine enhancer, particularly 4-iodophenol. ECL reactions are useful in diagnostic assay.

Abstract: An organolithium compound according to the present invention containing a cyclic amino group, has the general formula: ##STR1## wherein R.sub.1 is a divalent alkylene, an oxy- or amino-alkylene, or substituted alkylene having from 6 to about 20 carbon atoms; R.sub.2 is a linear-, branched-, or cyclo-alkylene having from about 2 to about 20 carbon atoms; and the lithium, Li, is bonded directly to a carbon atom of R.sub.2. A method of preparing an organolithium compound containing a cyclic amino group, comprising reacting a cyclic amino organo halide having the general formula ##STR2## where R.sub.1 and R.sub.2 are as above, and X is bromine or chlorine bonded directly to a carbon atom of R.sub.2, with a lithium reactant selected from lithium metal or an organolithium compound.

Abstract: The present invention relates to novel N,N'-difluorinated diazabicycloalkane derivatives which are useful as electrophilic fluorinating agents, processes for preparing such N,N'-difluorinated diazabicycloalkane derivatives and methods of using such compounds as fluorinating agents. The invention also presents novel N-fluorinated azaazoniabicycloalkane-Lewis acid adduct intermediates which are formed in the processes for preparing such N,N'-difluorinated diazabicycloalkane derivatives.